Leveraging Oral Solid Dose Technologies for the Development and Manufacturing of Potent Treatments

The discovery of new treatment modalities for oncology, neurology and rare diseases has seen a shift away from broad spectrum drugs in favor of more targeted, and often more potent drugs. One driver contributing to this growth is the rise of highly selective biological targeting mechanisms, which are capable of more precisely attacking only specific sites of action and can therefore be more potent than non-targeted treatments. However, converting such highly potent drug substances into drug products comes with formulation and process development challenges. With state-of-the-art containment and appropriate delivery technologies, such as oral solid dose technologies, highly potent drug products can be safely developed and manufactured into effective treatments.

Join this panel of industry experts as they delve into the driving forces that have created the recent surge in treatments for oncology and rare disease. Attendees will gain insights into the challenges and opportunities presented in the development and manufacturing of potent treatments. The featured speakers will discuss how the choice of appropriate oral solid dose technologies can help overcome development and manufacturing obstacles. Attendees will discover how industry leaders have utilized oral solid dose technologies through real-world case studies.

Speakers

Dr. Andreas Flückiger, Occupational Toxicology and Containment for the Pharmaceutical Industry

Dr. Flükieger is experienced in occupational health and toxicology, as well as process containment for pharmaceutical companies, with over 30 years as Chief Occupational Health Officer at F. Hoffmann-La Roche Ltd. Dr. Flükieger is currently consulting part-time and teaching while also holding a professorship at the Viennese Academy of Occupational Medicine and Prevention. Dr. Flükieger is actively involved in various task forces of ASTM, ISPE and ECA.

Message Presenter

Anshul Gupte, PhD, RAC-Drugs, Senior Director, Scientific and Technical Affairs, Catalent

Anshul Gupte is responsible for technical and scientific oversight of client projects. He works across various functional teams in RFP considerations and scope of work development, proposal delivery, client and prospective client meetings and contributes to the company’s thought leadership agenda. Most recently Anshul served as Senior Director, Drug Product Development for Mayne Pharma in Australia. Previously he worked with Metrics Contract Services in Greenville as Director of Pharmaceutical Development. Anshul holds a Bachelor of Pharmacy from the RGPV University, Bhopal, India, a Master of Science in Pharmaceutical Sciences from Temple University and a Doctorate in Pharmaceutical Sciences from the University of Kentucky.

Message Presenter